v3.22.2.2
Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Oct. 02, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Other Income and Expenses [Abstract]        
Interest income $ (70) $ (10) $ (114) $ (21)
Interest expense 311 325 925 975
Net interest expense 240 315 811 954
Royalty-related income (239) (261) (628) (649)
Net (gains)/losses on asset disposals 7 (1) 6 (99)
Net (gains)/losses recognized during the period on equity securities [1],[2] 112 (400) 1,353 (1,601)
Income from collaborations, out-licensing arrangements and sales of compound/product rights [3] (4) (65) (17) (317)
Net periodic benefit costs/(credits) other than service costs (306) (1,132) (294) (1,635)
Certain legal matters, net 77 38 175 112
Certain asset impairments [4] 200 0 200 0
Haleon/Consumer Healthcare JV equity method (income)/loss [5] 51 (105) (283) (307)
Other, net (198) (84) (260) (502)
Other (income)/deductions––net $ (59) $ (1,696) $ 1,063 $ (4,043)
[1] Reported in Other (income)/deductions––net. See Note 4.
[2] The losses in the first nine months of 2022 include, among other things, unrealized losses of $974 million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420 million and $1.5 billion, respectively, related to investments in BioNTech and Cerevel.
[3] The first nine months of 2021 included, among other things, $188 million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.
[4] The amount in the third quarter and first nine months of 2022 represents an intangible asset impairment charge associated with our Biopharma segment, representing an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA), acquired in our Array BioPharma Inc. acquisition. The intangible asset impairment charge was a result of the Phase 3 trial reaching futility at a pre-planned interim analysis.
[5] See Note 2C.